SCHEMBL13581995

SCHEMBL13581995

Cc1cc(C=CC(=O)O)cc(C)c1Oc1ccc(OCc2ccccc2Cl)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
SLC26A4 O43511 1/20 0.43
NR4A2 P43354 2/20 0.43
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
PTGER1 P34995 2/20 0.40
PTGER4 P35408 2/20 0.40
PTGER3 P43115 2/20 0.40
PTGER2 P43116 2/20 0.40
RECQL P46063 1/20 0.40
MAPT P10636 2/20 0.40
HPGD P15428 1/20 0.40
ALKBH1 Q13686 1/20 0.40
RHOA P61586 1/20 0.39
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13581992 1.00 KMT2A (0.43) KMT2AMEN1SLC26A4NR4A2MAOA
SCHEMBL2232811 0.96 KMT2A (0.42) KMT2AMEN1SLC26A4NR4A2MAOA
SCHEMBL2232819 0.96 KMT2A (0.42) KMT2AMEN1SLC26A4NR4A2MAOA
SCHEMBL13581865 0.90 RECQL (0.48) KMT2AMEN1SLC26A4NR4A2MAOA
SCHEMBL13581866 0.90 RECQL (0.48) KMT2AMEN1SLC26A4NR4A2MAOA
SCHEMBL13582345 0.88 PTPN1 (0.43) KMT2AMEN1MAOBRECQLMAPT
SCHEMBL13582347 0.88 PTPN1 (0.43) KMT2AMEN1MAOBRECQLMAPT
SCHEMBL13581821 0.87 CYP4F2 (0.43) KMT2AMEN1SLC26A4PTGER1PTGER4
SCHEMBL13581820 0.87 CYP4F2 (0.43) KMT2AMEN1SLC26A4PTGER1PTGER4
SCHEMBL2236662 0.86 NR4A2 (0.48) KMT2AMEN1NR4A2MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2528897-B9 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2015-04-22 EP disclosed
EP-2528897-B1 DI-SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMA CO LTD (JP) 2014-10-15 EP disclosed
US-8722663-B2 Di-substituted pyridine derivatives as anticancers OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-05-13 US disclosed
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-11-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120283242-A1 DI - SUBSTITUTED PYRIDINE DERIVATIVES AS ANTICANCERS TPD52L2, CCNE2, CDK2 KMT2A 686/4885MEN1 2854/4885SLC26A4 4260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.